## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPROVAL							
	OMB Number:	3235-0287						
l	Estimated average bur	den						
l	hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

							. 00()	00			onipany Act	0. 20 .0								
Name and Address of Reporting Person*  PERELMAN RONALD O						2. Issuer Name <b>and</b> Ticker or Trading Symbol  VTv Therapeutics Inc. [ VTVT ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
	1111111111	<u> </u>													Dire			X 10% C		
(Last) (First) (Middle) C/O MACANDREWS & FORBES INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 12/26/2017									Offic below	er (give title w)		Other below	(specify )	
35 EAST 62ND STREET					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X	Forn	n filed by On	ne Reporting Person			
NEW YO	ORK N	Y 1	10065												Forn Pers	n filed by Mo son	ore tha	an One Rep	orting	
(City)	(St	rate) (	Zip)																	
		Tabl	e I - N	lon-Deriv	ative	Sec	uritie	s Ac	quire	d, Di	isposed o	f, or E	Benefici	ally	Owne	ed				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y					Execution Date,		,	3. Transaction Code (Instr. 8)  4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a				Benefi		ties cially I Following	Forr (D) c	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)	Price		Transa	saction(s) r. 3 and 4)			(111511. 4)	
Class A common stock 12/26/201					017	17		P		50,000	A	\$4.034	<b>4</b> <sup>(1)</sup>	2,615,666				See footnote <sup>(2)</sup>		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transa Code ( 8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr	rative rities ired r osed )	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Со		Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares									

## Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from \$3.94 to \$4.19, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4.

2. Mr. Ronald O. Perelman is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of the Issuer by virtue of their relationship with Steven M. Cohen, Paul M. Meister and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

/s/ Barry F. Schwartz, attorneyin-fact 12/27/2017

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.